Loading stock data…
AORT
$36.21+0.38 (+1.06%)
Market ClosedLast close May 1
Artivion, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Artivion, Inc. in the Healthcare sector is trading at $36.21. The stock is currently 25% below its 52-week high of $48.25, remaining 10.9% below its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why AORT maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$36.21
Potential Downside
90.3%
Whystock Fair Value$3.52
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; C...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.80B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
176.95
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-4.00%
Volume
Today's trading volume
217,905
Recent News
3 Reasons to Avoid AORT and 1 Stock to Buy Instead
Over the last six months, Artivion’s shares have sunk to $37.03, producing a disappointing 18.2% loss - a stark contrast to the S&P 500’s 3.9% gain. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Strong Catalysts Drive Artivion (AORT)
Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive Small Cap valuations, but was impacted by volatility from Middle East geopolitical unrest and changing interest rate expectations. This unrest drove […]
How The Investment Story Is Shifting For Artivion (AORT) After Recent Analyst And FDA Updates
Artivion’s updated fair value estimate has shifted to $51.57 from $51.43, a small change that still matters if you are watching where analysts think the stock should land. This adjustment aligns with more constructive commentary from bullish analysts, who see a more attractive balance of risk and reward at current levels, while more cautious voices are trimming targets on execution and cost concerns. As you read on, you will see how these competing views shape the evolving narrative around...
1 Stock Under $50 to Own for Decades and 2 We Avoid
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Artivion Secures FDA Approval for NEXUS Aortic Arch System
AORT jumps after FDA approves NEXUS Aortic Arch System, unlocking a potential Endospan acquisition and advancing minimally invasive care for high-risk patients.